Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Protein changes in immunodepleted cerebrospinal fluid from a transgenic mouse model of alexander disease detected using mass spectrometry.

Posted by on in 2013
  • Font size: Larger Smaller
  • Hits: 1791
  • Print
Cunningham RJany PMessing ALi L. 2013 J Proteome Res. 12:719-28. doi: 10.1021/pr300785h. Epub 2013 Jan 11.

Department of Chemistry & School of Pharmacy, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.

Abstract

Cerebrospinal fluid (CSF) is a low protein content biological fluid with a dynamic range spanning at least 9 orders of magnitude in protein content and is in direct contact with the brain. A modified IgY-14 immunodepletion treatment was performed to enhance analysis of the low volumes of CSF that are obtainable from mice. As a model system in which to test this approach, we utilized transgenic mice that overexpress the intermediate filament glial fibrillary acidic protein (GFAP). These mice are models for Alexander disease (AxD), a severe leukodystrophy in humans. From the CSF of control and transgenic mice we report the identification of 289 proteins, with relative quantification of 103 proteins. Biological and technical triplicates were performed to address animal variability as well as reproducibility in mass spectrometric analysis. Relative quantitation was performed using distributive normalized spectral abundance factor (dNSAF) spectral counting analysis. A panel of biomarker proteins with significant changes in the CSF of GFAP transgenic mice has been identified with validation from enzyme-linked immunosorbent assay (ELISA) and microarray data, demonstrating the utility of our methodology and providing interesting targets for future investigations on the molecular and pathological aspects of AxD.

PMID:
23272901
[PubMed - in process]
PMCID:
PMC3568661
[Available on 2014/2/1]
Last modified on